NCT03780465View on ClinicalTrials.gov

A Study of Safety and Tolerability of NOX66 in Healthy Volunteers

PHASE1WithdrawnINTERVENTIONAL

0

Timeline

Start Date

March 1, 2019

Primary Completion Date

March 1, 2019

Study Completion Date

March 1, 2019

Conditions

Healthy Volunteers

Interventions

DRUG

Oral idronoxil suspension

Idronoxil powder up to 150 ml ORA-BLEND® flavoured syrup

DRUG

NOX66 (A)

Idronoxil formulated in suppository base A

DRUG

NOX66 (B)

Idronoxil formulated in suppository base B

Trial Locations (1)

3004

Nucleus Network Ltd, Melbourne

Sponsors

Lead Sponsor

Noxopharm Limited

All Listed Sponsors

lead

Noxopharm Limited

INDUSTRY